HK1207828A1 - 殘留的細胞 水平低的細胞來源的病毒疫苗 - Google Patents
殘留的細胞 水平低的細胞來源的病毒疫苗Info
- Publication number
- HK1207828A1 HK1207828A1 HK15108523.2A HK15108523A HK1207828A1 HK 1207828 A1 HK1207828 A1 HK 1207828A1 HK 15108523 A HK15108523 A HK 15108523A HK 1207828 A1 HK1207828 A1 HK 1207828A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- dna
- cell
- cell culture
- low levels
- residual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73278605P | 2005-11-01 | 2005-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207828A1 true HK1207828A1 (zh) | 2016-02-12 |
Family
ID=37969762
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09107245.9A HK1129837A1 (zh) | 2005-11-01 | 2009-08-07 | 經由β-丙內酯處理的殘留細胞 水平降低的細胞衍生病毒疫苗 |
HK15108523.2A HK1207828A1 (zh) | 2005-11-01 | 2015-09-01 | 殘留的細胞 水平低的細胞來源的病毒疫苗 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09107245.9A HK1129837A1 (zh) | 2005-11-01 | 2009-08-07 | 經由β-丙內酯處理的殘留細胞 水平降低的細胞衍生病毒疫苗 |
Country Status (19)
Country | Link |
---|---|
US (2) | US10655108B2 (zh) |
EP (3) | EP1951296B2 (zh) |
JP (5) | JP5602366B2 (zh) |
KR (1) | KR20080081254A (zh) |
CN (2) | CN101365480B (zh) |
AT (1) | ATE494906T1 (zh) |
AU (2) | AU2006310171B2 (zh) |
CA (1) | CA2627971A1 (zh) |
CY (1) | CY1111378T1 (zh) |
DE (1) | DE602006019629D1 (zh) |
DK (1) | DK1951296T4 (zh) |
EA (1) | EA014062B1 (zh) |
ES (2) | ES2359214T5 (zh) |
HK (2) | HK1129837A1 (zh) |
NZ (1) | NZ567817A (zh) |
PL (2) | PL1951296T5 (zh) |
PT (1) | PT2301572E (zh) |
SI (1) | SI1951296T2 (zh) |
WO (1) | WO2007052163A2 (zh) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101365480B (zh) * | 2005-11-01 | 2014-11-05 | 诺华疫苗和诊断有限两合公司 | 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗 |
KR20080089663A (ko) | 2006-01-27 | 2008-10-07 | 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
AU2007297178B2 (en) | 2006-09-11 | 2014-07-24 | Novartis Ag | Making influenza virus vaccines without using eggs |
NZ582595A (en) * | 2007-06-27 | 2012-07-27 | Novartis Ag | Low-additive influenza vaccines |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
NZ587798A (en) | 2008-03-18 | 2013-06-28 | Novartis Ag | Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer |
CA2741961A1 (en) * | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
DE102010018462A1 (de) | 2009-04-27 | 2011-04-07 | Novartis Ag | Impfstoffe zum Schutz gegen Influenza |
KR101800245B1 (ko) | 2009-05-21 | 2017-11-22 | 노파르티스 아게 | 비-내인성 pol i 프로모터를 사용하는 역 유전학 |
CN102666860B (zh) | 2009-07-31 | 2015-06-17 | 诺华股份有限公司 | 反向遗传*** |
WO2011044576A2 (en) | 2009-10-09 | 2011-04-14 | Children's Medical Center Corporation | Selectively disrupted whole-cell vaccine |
PL2491117T3 (pl) | 2009-10-20 | 2014-05-30 | Novartis Ag | Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę |
WO2011138229A1 (en) | 2010-05-03 | 2011-11-10 | Glaxosmithkline Biologicals S.A. | Novel method |
WO2011138682A2 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Organic peroxide compounds for microorganism inactivation |
JP5876036B2 (ja) | 2010-05-21 | 2016-03-02 | ノバルティス アーゲー | インフルエンザウイルス再集合方法 |
HUE051711T2 (hu) | 2010-06-01 | 2021-03-29 | Seqirus Uk Ltd | Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül |
PL2575873T3 (pl) | 2010-06-01 | 2016-06-30 | Novartis Ag | Zatężanie i liofilizacja antygenów szczepionkowych grypy |
SG188947A1 (en) | 2010-08-12 | 2013-06-28 | Yisheng Biopharma Holdings Ltd | Method for reducing dna impurities in viral compositions |
ES2531577T3 (es) | 2010-08-20 | 2015-03-17 | Novartis Ag | Conjuntos de agujas para la administración de vacuna soluble contra la gripe |
AU2012221740B2 (en) * | 2011-02-25 | 2016-11-17 | Novartis Ag | Exogenous internal positive control |
CN104093420B (zh) | 2011-11-03 | 2017-07-28 | 森提耐斯特治疗公司 | 针对人肠道病毒的抗原及疫苗 |
GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
EP2820126B1 (en) | 2012-03-02 | 2017-05-17 | Seqirus UK Limited | Influenza virus reassortment |
EP2822585B1 (en) | 2012-03-06 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Improved vaccination against influenza |
JP2015526062A (ja) | 2012-06-04 | 2015-09-10 | ノバルティス アーゲー | 改善された安全性試験 |
BR112015012380A2 (pt) | 2012-12-03 | 2017-09-12 | Novartis Ag | vírus influenza recombinante |
AU2014229255B2 (en) | 2013-03-13 | 2018-12-13 | Novartis Ag | Influenza B virus reassortment |
JP2016521282A (ja) | 2013-05-10 | 2016-07-21 | ノバルティス アーゲー | インフルエンザワクチンにおけるナルコレプシーのリスクの回避 |
DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
EP3004332A2 (en) | 2013-06-06 | 2016-04-13 | Novartis AG | Influenza virus reassortment |
US10080792B2 (en) | 2013-09-23 | 2018-09-25 | Engen Bio, Inc. | Influenza vaccine and therapy |
CN104436157A (zh) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
CN104513317B (zh) * | 2013-09-30 | 2018-12-14 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
KR20160068972A (ko) | 2013-11-15 | 2016-06-15 | 노파르티스 아게 | 잔여 세포 배양 불순물의 제거 |
WO2015179979A1 (en) * | 2014-05-28 | 2015-12-03 | National Health Research Institutes | Viral particles as immunogens against enterovirus infection and production thereof |
WO2016207853A2 (en) | 2015-06-26 | 2016-12-29 | Seqirus UK Limited | Antigenically matched influenza vaccines |
WO2017005880A1 (en) | 2015-07-07 | 2017-01-12 | Seqirus UK Limited | Influenza potency assays |
EP3184119A1 (en) * | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
CN109652384B (zh) * | 2019-02-21 | 2021-10-26 | 昆明理工大学 | 一种体外培养戊型肝炎病毒的方法 |
MX2022006005A (es) | 2019-11-18 | 2022-10-27 | Seqirus Pty Ltd | Metodo para producir virus de la influenza reagrupados. |
CN116407624B (zh) * | 2023-04-14 | 2024-04-09 | 吉林省农业科学院(中国农业科技东北创新中心) | 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4064232A (en) * | 1974-01-14 | 1977-12-20 | Sandoz Ltd. | Process for isolating the immunogenic components of influenza viruses |
CH589453A5 (zh) * | 1974-01-14 | 1977-07-15 | Sandoz Ag | |
CA1338800C (en) | 1986-06-17 | 1996-12-17 | Michael Houghton | Hepatitis delta and diagnostics and vaccines |
GB8703696D0 (en) * | 1987-02-18 | 1987-03-25 | Oxford J S | Influenza vaccine |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5010183A (en) | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
JP2941859B2 (ja) | 1989-09-20 | 1999-08-30 | 国立予防衛生研究所 | Ha蛋白の製造法 |
US5010112A (en) * | 1989-12-01 | 1991-04-23 | Massachusetts Institute Of Technology | Method and apparatus for improving the insulating properties of closed cell foam |
JP3108480B2 (ja) | 1991-09-25 | 2000-11-13 | 松下電工株式会社 | 多重伝送システムの割込処理方法 |
US5824536A (en) | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
ES2235489T3 (es) * | 1998-06-01 | 2005-07-01 | Chiron Corporation | Uso de polimeros de acido hialuronico para la administracion por las mucosas de antigenos y coadyuvantes de vacunas. |
JP2000230931A (ja) | 1998-12-07 | 2000-08-22 | Katakura Industries Co Ltd | 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット |
AU764969B2 (en) * | 1999-04-19 | 2003-09-04 | Smithkline Beecham Biologicals (Sa) | Vaccines |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
EP1878424A3 (en) | 1999-09-24 | 2008-04-09 | GlaxoSmithKline Biologicals S.A. | Novel vaccine |
EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
WO2001041814A1 (en) | 1999-12-08 | 2001-06-14 | Crucell Holland B.V. | Method of administering adenovirus |
AU3604201A (en) | 2000-03-03 | 2001-09-12 | Chemo Sero Therapeut Res Inst | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
US20040096463A1 (en) | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
WO2002074336A2 (en) | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
GB2386072A (en) | 2001-04-27 | 2003-09-10 | Becton Dickinson Co | Novel vaccine |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
DE10144903A1 (de) | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
AU2003231083A1 (en) * | 2002-04-26 | 2003-11-10 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
EP1590450A2 (en) | 2002-12-20 | 2005-11-02 | Crucell Holland B.V. | Recombinant virus production for the manufacturing of vaccines |
EP1618127B1 (en) * | 2003-04-10 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic composition comprising a spike protein of the SARS coronavirus |
EP1631663B1 (en) | 2003-05-28 | 2016-08-24 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines and gene therapy |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
EP1718738A2 (en) | 2004-02-23 | 2006-11-08 | Crucell Holland B.V. | Virus purification methods |
WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
CN101094915A (zh) | 2004-05-20 | 2007-12-26 | 益得生物医学公司 | 生产流感疫苗的方法 |
EP2179744B1 (en) * | 2004-09-09 | 2010-12-01 | Novartis Vaccines and Diagnostics GmbH | Decreasing potential latrogenic risks associated with influenza vaccines |
JP4031478B2 (ja) | 2004-12-13 | 2008-01-09 | プロテイン サイエンシーズ | インフルエンザ血球凝集素多価ワクチンの製造方法 |
JP5414178B2 (ja) | 2004-12-23 | 2014-02-12 | メディミューン,エルエルシー | ウイルス増殖用の非腫瘍形成性mdck細胞株 |
FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
CN101365480B (zh) * | 2005-11-01 | 2014-11-05 | 诺华疫苗和诊断有限两合公司 | 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗 |
-
2006
- 2006-11-01 CN CN200680046034.8A patent/CN101365480B/zh not_active Expired - Fee Related
- 2006-11-01 CA CA002627971A patent/CA2627971A1/en not_active Abandoned
- 2006-11-01 SI SI200630957T patent/SI1951296T2/sl unknown
- 2006-11-01 EP EP06831855.9A patent/EP1951296B2/en active Active
- 2006-11-01 DK DK06831855.9T patent/DK1951296T4/da active
- 2006-11-01 NZ NZ567817A patent/NZ567817A/en not_active IP Right Cessation
- 2006-11-01 US US12/092,190 patent/US10655108B2/en active Active
- 2006-11-01 DE DE602006019629T patent/DE602006019629D1/de active Active
- 2006-11-01 EP EP14183359.0A patent/EP2842572A1/en not_active Ceased
- 2006-11-01 KR KR1020087013164A patent/KR20080081254A/ko active Search and Examination
- 2006-11-01 CN CN201410631136.2A patent/CN104474543A/zh active Pending
- 2006-11-01 PT PT100755297T patent/PT2301572E/pt unknown
- 2006-11-01 ES ES06831855.9T patent/ES2359214T5/es active Active
- 2006-11-01 EA EA200801221A patent/EA014062B1/ru not_active IP Right Cessation
- 2006-11-01 WO PCT/IB2006/003880 patent/WO2007052163A2/en active Application Filing
- 2006-11-01 EP EP10075529.7A patent/EP2301572B1/en not_active Revoked
- 2006-11-01 AU AU2006310171A patent/AU2006310171B2/en active Active
- 2006-11-01 PL PL06831855T patent/PL1951296T5/pl unknown
- 2006-11-01 JP JP2008538454A patent/JP5602366B2/ja active Active
- 2006-11-01 ES ES10075529.7T patent/ES2525518T3/es active Active
- 2006-11-01 AT AT06831855T patent/ATE494906T1/de active
- 2006-11-01 PL PL10075529T patent/PL2301572T3/pl unknown
-
2009
- 2009-08-07 HK HK09107245.9A patent/HK1129837A1/zh unknown
-
2011
- 2011-04-05 CY CY20111100356T patent/CY1111378T1/el unknown
- 2011-04-29 AU AU2011201968A patent/AU2011201968B2/en active Active
- 2011-09-21 JP JP2011206634A patent/JP2011256209A/ja not_active Withdrawn
-
2014
- 2014-07-23 JP JP2014149517A patent/JP6639077B2/ja active Active
-
2015
- 2015-09-01 HK HK15108523.2A patent/HK1207828A1/zh unknown
-
2016
- 2016-07-25 JP JP2016145286A patent/JP7049761B2/ja active Active
-
2019
- 2019-10-23 JP JP2019192740A patent/JP2020023557A/ja active Pending
-
2020
- 2020-04-09 US US16/843,940 patent/US11466257B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207828A1 (zh) | 殘留的細胞 水平低的細胞來源的病毒疫苗 | |
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
WO2007024941A3 (en) | Polyvalent vaccine | |
MX2012001592A (es) | Composicion para el tratamiento de la infección del virus de la hepatitis b. | |
WO2012061815A3 (en) | RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs) | |
MX2012000035A (es) | Antigenos de virus de sincicio respiratorio recombinantes. | |
WO2010019262A3 (en) | Polyvalent vaccine | |
EA200870304A1 (ru) | Псевдоинфекционный флавивирус и его применение | |
WO2004112831A3 (en) | High titer recombinant influenza viruses for vaccines and gene therapy | |
WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
WO2006074303A3 (en) | Delivery vehicles, bioactive substances and viral vaccines | |
WO2011082388A3 (en) | Infectious dna vaccines against chikungunya virus | |
WO2010001409A3 (en) | Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same | |
EA201170533A1 (ru) | Высокодиспергируемый диоксид кремния для резин и способ его получения | |
WO2011106607A3 (en) | Subunit vaccines for herpes viruses and methods of use | |
WO2010095041A3 (en) | Compositions, methods, and kits for treating influenza viral infections | |
PH12015501378A1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
MX2010006984A (es) | Vacunas contra la malaria. | |
WO2008115314A3 (en) | Flavivirus vaccine vector against influenza virus | |
WO2007082734A3 (en) | Influenza vaccine | |
TW200531701A (en) | Method of vaccination against testicular BVDV infection | |
WO2008002152A3 (en) | Process for culturing bacteria of the piscirickettsia genus | |
WO2007028985A3 (en) | Adjuvanted vaccine | |
WO2007104263A8 (zh) | 一种乙型肝炎病毒疫苗增效蛋白及其基因 | |
MX2012002702A (es) | Vacuna de herpesvirus bovino. |